Designation is supported by an exploratory analysis from the Phase 1b study showing that some children with SMA previously treated with gene therapy who had suboptimal clinical status experienced ...
The FDA's decision follows data from a Phase Ib study on salanersen.
Biogen has announced that salanersen has been given the US FDA Breakthrough Therapy Designation to treat spinal muscular ...
Biogen’s salanersen receives US FDA breakthrough therapy designation for SMA: Cambridge, Massachusetts Saturday, June 6, 2026, 15:00 Hrs [IST] Nasdaq-listed drug major Biogen In ...
Vertex Pharmaceuticals announced the FDA has accepted its biologics license application submission for povetacicept, an ...
CureDuchenne, a global nonprofit based in Newport Beach committed to finding and funding a cure for Duchenne muscular ...
University of Maine researchers have published new findings about how muscles form, why certain muscle diseases develop and ...
A drug called apitegromab may help preserve lean body mass during weight loss with tirzepatide, a GLP-1 receptor agonist, ...
University of Maine researchers have published new findings about how muscles form, why certain muscle diseases develop and ...
In a clinical trial, an experimental antibody reduced lean-mass loss in people on a GLP-1 drug. Whether that improves health ...
9hon MSN
Alterity Therapeutics advances lead drug towards pivotal study for rare neuromuscular disorder
Alterity Therapeutics Limited ATHE stock is up during Tuesday’s session as the biotechnology company announced an ...
Worldwide Healthcare Trust PLC - Annual Financial Report PR Newswire LONDON, United Kingdom, June 05 4 June 2026 Worldwide ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results